格隆汇11月21日丨昊帆生物(301393.SZ)公布，第四届董事会第十四次会议、第四届监事会第十二次会 议，分别审议通过了《关于变更部分募集资金用途和部分募投项目结项的议案》和《关于部分募投项目 延期的议案》，具体包括：1."苏州昊帆生物股份有限公司100kg/年多肽、蛋白质试剂研发与生产及总部 建设项目（一期）"基本达到预定可使用状态，本次拟结项，节余资金用于补充流动资金。2.受外部政 策变化的影响，结合公司现阶段经营发展的需要，公司拟变更现有募投项目"安徽昊帆多肽试剂及医药 中间体建设项目"和"多肽及蛋白质试剂研发平台建设项目"中合计49,696.68万元募集资金的用途，投入 于另一募投项目"淮安昊帆生产基地建设项目"的建设；同时，"安徽昊帆多肽试剂及医药中间体建设项 目"和"多肽及蛋白质试剂研发平台建设项目"拟结项，扣除上述变更募集资金金额后的节余资金（系现 金管理收益扣除手续费的净额）用于补充流动资金。3.为保障产能建设安全、快速、有序推进，公司决 定分期建设淮安昊帆生产基地的生产线，因此"淮安昊帆生产基地建设项目"拟延长达到预定可使用状态 的时间至2028年12月。 ...

格隆汇11月21日丨昊帆生物(301393.SZ)公布，第四届董事会第十四次会议、第四届监事会第十二次会 议，分别审议通过了《关于变更部分募集资金用途和部分募投项目结项的议案》和《关于部分募投项目 延期的议案》，具体包括：1."苏州昊帆生物股份有限公司100kg/年多肽、蛋白质试剂研发与生产及总部 建设项目（一期）"基本达到预定可使用状态，本次拟结项，节余资金用于补充流动资金。2.受外部政 策变化的影响，结合公司现阶段经营发展的需要，公司拟变更现有募投项目"安徽昊帆多肽试剂及医药 中间体建设项目"和"多肽及蛋白质试剂研发平台建设项目"中合计49,696.68万元募集资金的用途，投入 于另一募投项目"淮安昊帆生产基地建设项目"的建设；同时，"安徽昊帆多肽试剂及医药中间体建设项 目"和"多肽及蛋白质试剂研发平台建设项目"拟结项，扣除上述变更募集资金金额后的节余资金（系现 金管理收益扣除手续费的净额）用于补充流动资金。3.为保障产能建设安全、快速、有序推进，公司决 定分期建设淮安昊帆生产基地的生产线，因此"淮安昊帆生产基地建设项目"拟延长达到预定可使用状态 的时间至2028年12月。 ...

截至发稿，河化股份市值为27亿元。 每经头条（nbdtoutiao）——展望"十五五" | 专访黄群慧：既要重视AI赋能千行百业，也要考量其对就业 的替代效应和带来的收入极化 （记者 曾健辉） 每经AI快讯，河化股份（SZ 000953，收盘价：7.5元）11月21日晚间发布公告称，公司第十一届第四次 董事会会议于2025年11月21日在公司本部三楼会议室以现场及视频方式召开。会议审议了《关于聘任 2025年会计师事务所的议案》等文件。 2025年1至6月份，河化股份的营业收入构成为：医药中间体占比50.94%，化工行业占比48.99%，其他 业务占比0.08%。 ...

11月21日，东亚药业跌5.04%，截至发稿，报19.58元/股，成交1490.50万元，换手率0.66%，总市值 22.46亿元。东亚药业股价已经连续3天下跌，区间累计跌幅3.87%。 资料显示，浙江东亚药业股份有限公司位于浙江省台州市临海市台州湾经济技术开发区东海第五大道21 号，成立日期1998年2月6日，上市日期2020年11月25日，公司主营业务涉及化学原料药、医药中间体的 研发、生产和销售。主营业务收入构成为：β-内酰胺类抗菌药44.84%，抗胆碱和合成解痉药23.92%， 喹喏酮类抗菌药12.86%，皮肤用抗真菌药8.87%，其他产品5.05%，其他(补充)4.46%。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模18.55亿。今年以来收益73.37%，同类 排名205/8136；近一年收益70.11%，同类排名214/8056；成立以来收益234.6%。 诺安多策略混合A（320016）基金经理为孔宪政。 截至发稿，孔宪政累计任职时间4年361天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 95.2%， 任职期间最差基金回报-16.74%。 风险提示：市场有 ...

Company Overview - Xi'an Ruile New Materials Co., Ltd. is located in Xi'an High-tech Zone, Shaanxi Province, and was established on April 15, 1999. The company was listed on September 2, 2020. Its main business involves the research, development, production, and sales of specialized organic new materials [1]. - The company's revenue composition includes display materials (77.97%), pharmaceutical intermediates (18.63%), and others (3.41%) [1]. Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 1.301 billion yuan, representing a year-on-year growth of 19.01%. The net profit attributable to the parent company was 281 million yuan, showing a year-on-year increase of 51.54% [2]. - Since its A-share listing, the company has distributed a total of 498 million yuan in dividends, with 300 million yuan distributed over the past three years [3]. Stock Performance - As of November 18, the company's stock price was 46.98 yuan per share, with a market capitalization of 8.155 billion yuan. The stock has increased by 53.03% year-to-date, but has seen a decline of 1.72% over the last five trading days and 1.32% over the last twenty days [1]. - The stock's trading volume on November 18 was 44.8366 million yuan, with a turnover rate of 0.55%. The net outflow of main funds was 8.522 million yuan [1]. Shareholder Information - As of November 10, the number of shareholders was 10,000, a decrease of 5.73% from the previous period. The average circulating shares per person increased by 6.08% to 17,278 shares [2].

Core Viewpoint - The company, Lite Optoelectronics, is raising up to 766 million yuan through convertible bonds to enhance its technological capabilities and industry competitiveness, focusing on new material R&D, smart workshop upgrades, and working capital supplementation [1][3]. Group 1: Fundraising and Investment Projects - The largest project in the fundraising plan is the construction of a new materials R&D base in Pucheng, with a total investment exceeding 520 million yuan, of which 500 million yuan will be raised from the bond issuance [2]. - The second key project involves the smart upgrade of production workshops, with a total investment of 35.8469 million yuan, aiming to enhance production efficiency and safety through automation and system optimization [2]. - An additional 32 million yuan is allocated for the development and verification platform for perovskite materials, aimed at accelerating the transition from R&D to mass production in the new photovoltaic materials sector [2]. Group 2: Business Performance and Market Position - In the first three quarters of the year, Lite Optoelectronics reported a cumulative revenue of 423 million yuan, representing an 18.77% year-on-year increase, and a net profit attributable to shareholders of 180 million yuan, up 38.62% year-on-year [1]. - The company has established a complete industrial chain in the OLED organic materials sector, from material design to device testing, and is one of the few domestic companies capable of independent R&D and mass production of OLED terminal materials [1][3]. - Lite Optoelectronics' products are integrated into the supply chains of major domestic panel manufacturers and have expanded into overseas markets, indicating a strong competitive position in the high-end organic materials industry [1][3].

Core Viewpoint - The company, Lite-On Optoelectronics, is accelerating its industrial layout in the OLED sector by planning to issue convertible bonds to raise up to 766 million yuan, marking a significant step towards its new development phase and reflecting its commitment to expanding in OLED materials and emerging business areas [1][2][3]. Group 1: Fundraising and Investment Plans - Lite-On Optoelectronics plans to issue convertible bonds totaling no more than 766 million yuan with a maturity of 6 years, aiming to fund several key projects [2]. - Of the raised funds, 500 million yuan will be allocated to the construction of new material production bases, enhancing the production capacity of OLED intermediates and other materials [2]. - The company will invest 34 million yuan in upgrading production facilities to improve automation and efficiency, and 32 million yuan in developing a platform for perovskite materials [2][3]. Group 2: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 423 million yuan, an increase of 18.77% year-on-year, and a net profit of 180 million yuan, up 38.62% year-on-year [1][3]. - The net profit excluding non-recurring items reached 170 million yuan, reflecting a significant growth of 46.51% year-on-year [1][3]. - The growth in revenue is primarily driven by increased sales of OLED terminal materials, supported by strong demand in various applications such as smartphones and automotive displays [3]. Group 3: Cost Management and Efficiency - The company has implemented cost reduction and efficiency enhancement strategies, resulting in an 8.75% decrease in operating costs for the first three quarters, which contributed to a 39.08% increase in total profit [4]. - The gross profit margin has improved, with quarterly profit growth reaching 44.98% [4]. Group 4: Research and Development Focus - Lite-On Optoelectronics emphasizes research and development as a core driver of growth, with R&D expenditures amounting to 49.29 million yuan in the first three quarters, a year-on-year increase of 12.39% [5]. - The R&D investment in the third quarter alone was 17.22 million yuan, reflecting a significant growth rate of 24.24% [5]. - R&D spending accounted for 13.12% of revenue in the third quarter, indicating a strong commitment to innovation [5][6]. Group 5: Future Outlook - The company aims to leverage the upcoming convertible bond issuance to enhance production capacity, optimize product structure, and strengthen technological innovation, positioning itself to benefit from the rapid growth of the domestic OLED industry [6]. - With a focus on building a self-controlled supply chain in OLED materials, the company is set to contribute significantly to the independent development of the OLED industry in China [6].

Group 1 - A total of 106 stocks in the A-share market hit the daily limit, with 86 stocks hitting the limit after excluding 20 ST stocks, resulting in an overall limit-up rate of 70.2% [1] - Victory Co., Ltd. had the highest limit-up order volume at 764,100 hands, while 36 stocks had limit-up order funds exceeding 100 million yuan, with Tinci Materials, Furui Shares, and Suda Shares leading in order funds at 573 million yuan, 451 million yuan, and 428 million yuan respectively [1][2] Group 2 - Tinci Materials closed at 47.20 yuan with a turnover rate of 10.02%, achieving a limit-up order volume of 121,400 hands and order funds of 573 million yuan, driven by long-term contracts for electrolytes and lithium hexafluorophosphate [2] - Furui Shares closed at 10.51 yuan with a turnover rate of 1.92%, achieving a limit-up order volume of 429,500 hands and order funds of 451 million yuan, attributed to electrolyte additives and equity unfreezing [2] - Suda Shares closed at 48.84 yuan with a turnover rate of 22.11%, achieving a limit-up order volume of 87,600 hands and order funds of 428 million yuan, supported by coal equipment and overseas expansion [2]

Core Viewpoint - Jiangxi Yuhua Pharmaceutical Co., Ltd., a subsidiary of Jingdezhen Black Cat Group, has been re-evaluated and recognized as a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Jiangxi Province due to its strong technical foundation and market performance in the pharmaceutical and chemical industry [1] Group 1: Company Overview - Yuhua Company has evolved from a small chemical synthesis plant to a comprehensive pharmaceutical and fine chemical enterprise, focusing on the production of active pharmaceutical ingredients, pharmaceutical intermediates, organic solvents, and chemical raw materials [1] - In 2018, the company relocated to a new facility in the high-tech zone, equipped with advanced safety, environmental protection, and wastewater treatment facilities that meet strict national environmental and safety standards [1] Group 2: Achievements and Certifications - In March 2022, Yuhua Company received the Certificate of Suitability for European Pharmacopoeia (CEP) for Piracetam from the European Medicines Agency and completed drug registration in Russia [1] - The company has been recognized as a provincial benchmark enterprise for water conservation, a provincial "specialized, refined, distinctive, and innovative" small and medium-sized enterprise, and a provincial specialized small giant enterprise, highlighting its core competitiveness in niche markets [1]

近日，九江善水科技股份有限公司（以下简称"善水科技"）发布公告称，收到实际控制人的通知，获悉经法院调解，黄国荣和吴新艳双方已解除婚姻关系， 并就股份分割等事宜做出相关安排。 具体来看，此次股份分割，黄国荣名下直接持有的股份中1000万股分割到吴新艳名下。黄国荣间接持有的股份，包括正祥投资财产份额2100万元（占合伙企 业份额97.3123%）分割到吴新艳名下，黄国荣名下泽祥睿宝投资财产份额690万元（占合伙企业份额38.6685%）也划归吴新艳名下。 本次权益变动后，黄国荣直接持有3000万股善水科技股票（占总股本的13.9771%），合计直接及间接持有3022.2万股股票（占总股本的14.0806%）；吴新艳 直接持有3500万股善水科技股票（占总股本的16.3066%），直接及间接持有6856.8万股股票（占总股本的31.9461%）。 值得关注的是，在此次股权分割之前，吴新艳合计直接及间接持有3066.8万股善水科技股票，分割后吴新艳拟合计收到3790万股善水科技股票。11月7日， 善水科技收盘价为24.38元/股，据此计算，吴新艳将获得的股权市值约9.24亿元。 与此同时，吴新艳成为善水科技的实际控制 ...